Antigen-presenting cells (APC), such as macrophages and dendritic cells, capture sufficient antigen from dead tumor cells via phagocytosis, activate T cells while initiating anti-cancer immunity, thus exerting an important effect on immune checkpoint therapy (Salmon et al., 2016), while tumor STC1 impairs membrane CRT-mediated by reducing the levels of cell membrane calreticulin (CRT) and thus APC phagocytosis and T cell activation, inhibiting tumor immunity and immunotherapy (Lin et al., 2021). Here, STC1 is linked to neoplasm.